•  
  •  
image-723919-Mission_AD_logo.jpg
image-723919-Mission_AD_logo.jpg
                       
               NCT03887455


What follows is a brief summary of the Eisai Pharmaceuticals AHEAD 3-45 (CLARITY) trial of BAN2401, a monoclonal antibody that binds to large oligomers, called protofibrils, and neutralizes their damage to brain cells

  • Drug administration -- IV infusion every 2 weeks     

  • Age range -- 50-90

  • MMSE range -- 22-30

  • Study Duration -- 18 mos.

  • Target population -- Mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD) and postive measure of brain amyloid pathology                                         

  • Mechanism of action --  blocks formation of active beta amyloid protein (BACE inhibition)

  • Randomization split -- 1:1,  active : placebo

  • Type(s) of imaging -- brain MRI, CT, amyloid PET, Tau PET


For more details on this specific trial, visit:


ClinicalTrials.gov
                                                                         
             A service of the U.S. National Institutes of Health

Donald S. Marks, M.D., P.C. -- 45 Resnik Road, Suite 205 -- Plymouth, MA, 02360

Tel: (508) 746-5060   Fax: (508) 746-8060